Search results
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Zacks via Yahoo Finance· 2 months agoRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes...
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
Motley Fool via Yahoo Finance· 6 months agoIt's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big...
Is CRISPR Therapeutics Stock a Buy Now?
Motley Fool· 1 year agoGene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) has significantly lagged the market over the past year, but there are reasons to be optimistic...
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
Investor's Business Daily· 7 months agoWhen looking for the best stocks to buy and watch, focus on those with rising relative price...
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
Zacks via Yahoo Finance· 1 year agoCRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.94, moving +0.56% from the...
Crispr Therapeutics Stock: Bull vs. Bear
Motley Fool· 2 years agoCrispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology. The biotech company is submitting its candidate to...
Better Growth Stock: CRISPR Therapeutics vs. Teladoc Health
Motley Fool· 1 year agoCRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to...
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
Motley Fool· 6 months agoCRISPR Therapeutics' (NASDAQ: CRSP) stock has soared this year -- and for good reason. The biotech...
CRISPR Therapeutics Stock Sees Relative Strength Rating Rise To 89
Investor's Business Daily· 1 year agoOne important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR...
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights CRISPR Therapeutics' estimated fair value is US$64.30 based on 2 Stage Free Cash Flow...
